Press Releases
Gateway Genomics Ranks 296 in the Inc. 5000 Fastest-Growing Private Companies in America List for 2020
For the second straight year, Gateway Genomics ranks in the top 25 private companies in the Health sector, which includes biotech, pharmaceutical firms, and makers of medical devices and products for the health care market.
Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces inclusion in the Inc. 5000 2020 list of fastest growing private companies for the second year in a row. To qualify, companies must have been founded and generating revenue by March 31, 2016. Ranking in the list is determined by the percentage revenue growth from 2016 to 2019, with minimums set for each year. With 1,623% revenue growth from 2016 to 2019, Gateway Genomics ranked #296 in the list, and #22 in the Health sector.
Gateway Genomics Announces Top 7 Reasons Why Women Want to Know Their Baby’s Gender Early
In a new study with over 1,000 participants across the US, UK, and Canada, “satisfying curiosity” was the #1 reason for fetal sex determination at 8 weeks into pregnancy.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces a new publication titled, “Reported Benefits of Early Fetal Sex Determination” in the International Journal of Pregnancy & Child Birth. In the study, over 1,000 postpartum moms who had taken the SneakPeek Early Gender DNA Test responded to a survey to share what benefits they received from knowing the gender of their babies early in pregnancy.
Gateway Genomics Announces Partnership with Any Lab Test Now, Increasing Accessibility of the SneakPeek Early Gender DNA Test
The collaboration greatly expands SneakPeek’s distribution network across the US, making it easier than ever for parents to learn the gender of their baby at 8 weeks into pregnancy.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, teams with Any Lab Test Now, a leading provider of convenient and affordable lab testing services, to offer SneakPeek Early Gender DNA tests.
Gateway Genomics Announces New SneakPeek Early Gender DNA Test Website
Ecommerce company sees sales expand as customers move to online shopping for a fetal sex test that can be taken from the safety of home.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces the launch of an updated website at sneakpeektest.com.
Gateway Genomics Surpasses 200,000 SneakPeek Early Gender DNA Tests Sold with the Acceleration of At-Home Kit Purchases
The prominent sales milestone was achieved last month as families seek alternative proven methods to learn the fetal sex of their babies from the comfort of home.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, reached 200,000 SneakPeek Early Gender DNA Tests sold in March, just months after attaining the 150,000-test landmark in late 2019.
Gateway Genomics Ranks No. 17 in the Inc. 5000 Series: California’s Fastest-Growing Private Companies for 2020
With a two-year revenue increase of 861%, Gateway Genomics emerged as the fastest-growing biotech company in California.
Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, was recognized in last year’s annual Inc. 5000 list of fastest-growing private companies in the United States.
Gateway Genomics Attends Maternity & Midwifery Festival in London to Expand Market for SneakPeek Clinical Early Gender DNA Test in the UK
Non-invasive prenatal test (NIPT) SneakPeek Clinical identifies fetal sex at 8 weeks gestational age, weeks earlier than any other method.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, attended the 2020 session of the London Maternity & Midwifery Festival in January to share the benefits SneakPeek Clinical can bring to the patients of midwifery professionals.
Gateway Genomics Surpasses 500 Clinical Locations Across the US and UK
Clinical sales revenue continues to accelerate as the company opens SneakPeek to new channels.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, has achieved a milestone of over 500 distributors of its SneakPeek Clinical test across the US and UK. Originally focusing on medical offices, the company has expanded its early gender DNA test offering to independent labs that carry a range of genetic tests.
Gateway Genomics Launches SneakPeek Early Gender DNA Test in Australia
This expansion makes accurate, affordable fetal sex determination at 8 weeks into pregnancy available to Australian families for the first time.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces that the SneakPeek DNA test is now available to Australian mums to learn the gender of their babies as early as 8 weeks into pregnancy.
Gateway Genomics Continues Upward Momentum in Q4 2019 With Over 150,000 SneakPeek Early Gender DNA Tests Sold
The prominent sales milestone was achieved this month as clinical revenue accelerates and the company prepares to launch SneakPeek in Australia.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, reached 150,000 SneakPeek Early Gender DNA Tests sold, just five months after attaining the 100,000-test landmark in June.